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Inflammatory markers and acute phase reactants (from here referred to as “markers”) are 
associated with COVID-19 infection and may be able to predict disease severity.1,2 We collected 
markers including d-dimer (ug/mL), ferritin (ng/mL), CRP (mg/dL), and creatinine kinase (CK) 
(IU/L) on admission and periodically throughout the hospital stay for 50 patients admitted with 
COVID-19 infection. We hypothesized that higher levels of markers at admission and during 
hospitalization are associated increased severity of disease, such as ICU admission and 
placement on mechanical ventilation.
From March to May 2020, we identified 50 patients admitted to Providence St. Vincent Medical Center with 
PCR-confirmed COVID-19 infection. Demographic and laboratory data were obtained through chart review. 
Statistical analysis including linear regression, t-tests, and chi2 tests were performed to look at the association 
between markers and severe outcomes including ICU admission, mechanical ventilation, and inpatient 
mortality. Regression models were adjusted for patients’ age, gender, DM2 status, reported onset of symptoms, 
and whether the patient was hypoxic at admission. All the statistical analyses were carried out by STATA 
software (Version 16.1; STATA Corporation, College Station, TX, USA).
There were 50 patients admitted for COVID-19 infection in March-May 2020. The average age 
was 60 yrs, and 46% (23) were female. Average reported duration of symptoms at admission 
was 7.9 days. 69% (33) of patients were hypoxic at admission, with SpO2 of <90% or requiring 
supplemental oxygen. 36% (n=18) of patients were admitted to the ICU during this time period. 
28% (14) of patients were placed on mechanical ventilation, and 12% (6) died during their 
hospitalization (Table 1). 
• The difference in mean admission markers between patients that were and were not 
hypoxic at admission were not statistically different. 
• Patients who were admitted to the ICU had significantly higher ferritin levels at admission 
(ferritin difference 864.7, p=0.04); they also had significantly elevated peak CRP, ferritin, and 
CK, in comparison to patients admitted to the floor (CRP difference 13.6, p=0.01; Ferritin 
difference 1071.7; p=0.01, CK difference 561, p=0.03). 
• Patients who had to be placed on mechanical ventilation had significantly higher CRP and 
ferritin levels at admission (CRP difference 21.5, p=0.04; ferritin difference 958.7, p=0.03); 
patients on mechanical ventilation also had increased peak levels of all markers (CRP 
difference 13.6, p=0.01, ferritin difference 1071.7, p=0.01; d-dimer difference 5.1, p=0.05; 
CK difference 626.3, p=0.02). 
• Patients who died while in patient had higher d-dimer levels at admission (d-dimer 
difference 7.4, p=0.001); there was a trend in significance in the difference between peak 
CRP and ferritin levels among patients who died while inpatient. 
So while clinical features such as hypoxia are often indicators for increased surveillance (ICU admission) and mechanical intubation, elevated markers such as CRP, ferritin, d-dimer and CK are also associated with ICU admission 
and mechanical ventilation. Elevation in inflammatory markers such as CRP and ferritin have been demonstrated among severe cases of COVID-19 previously (Zeng, 2020). Surprisingly, different levels of inflammatory markers were 
not different among those presenting with and without hypoxia. Thus, inflammatory markers could be early warning signs for whether a COVID 19+ patient should be admitted, monitored at home, or triaged further. Similar to other 
studies, we found increasing levels of d-dimer was associated with mortality in COVID 19 patients.3
Limitations to this study include small sample size, differences in practices of collecting laboratory samples over time (more samples were collected in ICU patients in comparison to floor patients). These markers were collected 
for exploratory analysis, not for decision making in the majority of cases, thus there was no uniform protocol for collecting markers. Overall, tracking markers may be useful in determining the severity of COVID-19 infection and 
ascertaining disposition. The effect of dexamethasone on inflammatory markers remains to be determined, as our cases are from before the RECOVERY trial. 
Next steps in furthering this research include:
• Ascertain levels at which patients are more likely to be admitted to ICU or require mechanical ventilation (could also match markers with P:F ratios). 
• Determine if there is a certain level at which steroids may be of benefit.
• Determine if these markers may be used to track duration of therapy and when therapy can be stopped.
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Table 1: Descriptive statistics
Mean age (yrs) 60.26
Average reported duration of 




% hypoxic at admission (n)
68.8% 
(33)
% with DM2 (n) 27% (13)
% female (n) 46% (23)
% admitted to ICU (n)
36% (18)














































































Average ferritin at presentation by whether patient 
was admitted to the ICU vs. the floor
Average Peak D-dimer by whether patients died 
inpatient or survived during study period
Average Peak D-dimer by whether patients died 
inpatient or survived during study period
